<DOC>
	<DOCNO>NCT01871207</DOCNO>
	<brief_summary>Some study recently show concentration erythropoietin vitreous humor diabetic patient suffer diabetic retinopathy high non-diabetic patient . It report high concentration erythropoietin vitreous humor blood , indicate local production . In case also find positive association concentration Erythropoietin Vascular Endothelial Growth Factor ( VEGF ) . Both factor , erythropoietin VEGF , show important angiogenic activity may play role development diabetic retinopathy . This study enrol type 2 diabetic patient PDR undergo vitrectomy period May 2011-January 2012 Unit Ophthalmology , A.O . Civil Hospital University Brescia . Inclusion criterion follow : type 2 diabetes , age great 18 year , PDR ; exclusion criterion : age le 18 year , type 1 diabetes , initial DR , PDR patient require surgery , previous vitrectomy eye examination ophthalmic surgery laser therapy within previous 3 month . Non-diabetic patient underwent vitrectomy macular hole pucker represent control group ( CTRLs ) ; inclusion criterion : age great 18 year presence macular pucker macular hole require vitrectomy . Exclusion criterion : age le 18 year , diagnosis diabetes mellitus , previous vitrectomy eye examination ophthalmic surgery laser therapy within previous 3 month . All patient underwent complete ophthalmologic examination ( visual acuity , slit lamp , tonometry , fluorescein retinal angiography , optical coherence tomography -OCT- ) . Informed consent obtain patient detailed description aim procedure study . The following data record patient : 1 . Population : age ( year ) , sex ( M/F ) ; 2 . Clinical : diabetes ( Absent Type 2 ) ; time since initial diagnosis diabetes ( year ) ; type therapy DM : diet , oral hypoglycaemic agent , mixed ( oral agent insulin , insulin ) ; hypertension ( define systolic blood pressure &gt; 140 diastolic blood pressure &gt; 90 mmHg antihypertensive drug ) ; current ( Yes/No ) antihypertensive therapy ; use angiotensin II receptor blocker ( ARB ) angiotensin convert enzyme inhibitor ( ACE-i ) ; presence hypercholesterolaemia , comorbidities , therapy statin ( Yes/No ) , anticoagulant ( Yes/No ) , antiplatelet therapy ( Yes/No ) ; therapy perform , smoke ( non-smoker , active smoker ) ; complication diabetes mellitus present time evaluation ( heart disease , nephropathy , neuropathy ) ; 3 . Ocular : eye ( OD/OS ) ; visual acuity ; presence grade diabetic retinopathy ; presence emovitreo ; presence diabetic macular oedema ; presence cataract lens implant ; intervention phacoemulsification vitrectomy ; presence retinal disease , concomitant eye disease ; performance previous retinal laser therapy , intravitreal injection Avastin vitrectomy ; 4 . Biochemical : Haemoglobin ( g/dL ) ; glucose ( mg/dL ) ; glycated haemoglobin ( % ) ; platelet ( N/mmc ) ; creatinine ( mg/dL ) ; albuminuria ( mg/day ) , creatinine clearance ( mL/min ) , calculate Modification Diet Renal Disease ( MDRD ) formula ; total cholesterol ( mg/dL ) ; HDL LDL ; triglyceride ( mg/dL ) . All patient underwent 23- 25-gauge par plana vitrectomy . The primary outcome study measurement EPO VEGF concentration serum vitreous aqueous humor . Blood sample , take surgery , centrifuge 3000 rpm 10 minute separate serum fraction , store -80°C . Aqueous vitreous humor take surgery immediately frozen -80°C . Both EPO VEGF concentration measure serum vitreous humor ; however , owe small amount sample , EPO concentration determine aqueous humor . EPO assay radioimmunoassay ( Immulite EPO 200 , Siemens ) , low detection limit 1.0 mIU/mL . VEGF assay ELISA ( Human VEGF Immunoassay , R &amp; D Systems Europe , Abingdon , UK ) low limit detection 10.0 pg/mL . VEGF concentration low limit detection set 5 pg/mL perform statistical analysis . VEGF value 2000 pg/mL set 2500 pg/mL ; statistical test also perform delete data 2000 pg/mL .</brief_summary>
	<brief_title>Serum Intraocular Levels Erythropoietin VEGF Type 2 Diabetes Patients With Proliferative Retinopathy</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>CASE Inclusion criterion : type 2 diabetes , age great 18 year , PDR . Exclusion criterion : age le 18 year , type 1 diabetes , initial DR , PDR patient require surgery , previous vitrectomy eye examination ophthalmic surgery laser therapy within previous 3 month . CONTROL Inclusion criterion : age great 18 year presence macular pucker macular hole require vitrectomy . Exclusion criterion : age le 18 year , diagnosis diabetes mellitus , previous vitrectomy eye examination ophthalmic surgery laser therapy within previous 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Erythropoietin ( EPO )</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>Vascular Endothelial Growth Factor ( VEGF )</keyword>
	<keyword>Erythropoiesis Stimulating Agents ( ESA )</keyword>
</DOC>